Abstract
Hypersensitivity Pneumonitis (HSP) is an immune-mediated interstitial lung disease that presents significant diagnostic challenges due to its lack of pathognomonic symptoms. This study examines the diagnostic accuracy of HSP in the presence of comorbid Ischemic Heart Disease (IHD). A retrospective analysis of 87 patients revealed that IHD significantly exacerbates diagnostic errors, with rates rising from 44.88% in isolated HSP cases to 60.49% in comorbid cases. The "masking" effect of cardiac symptoms, misinterpretation of imaging, and underutilization of diffusion capacity tests contribute to delays in correct diagnosis of up to two years.
Introduction
Hypersensitivity Pneumonitis (HSP) is a complex interstitial lung disease (ILD) triggered by an exaggerated immune response to inhaled organic antigens or low-molecular-weight chemicals. Common triggers include mold, bird droppings, and various industrial resins. Despite its potential severity, HSP is notoriously difficult to diagnose, with general clinical error rates reaching as high as 75%.
The diagnostic landscape becomes even more treacherous when patients present with comorbid Ischemic Heart Disease (IHD). Both conditions share primary symptoms—most notably dyspnea (shortness of breath) and fatigue—leading to a clinical "masking" effect. This paper explores the specific mechanisms of diagnostic failure when these two conditions coexist and highlights the resulting delays in patient care.
Methodology
The study involved a retrospective analysis of 87 patient records sourced from City Clinical Hospital (GKB) 24 in Moscow and the Central Scientific Research Institute of Tuberculosis. The cohort was divided into two distinct groups for comparison:
- Main Group (n=39): Patients diagnosed with both HSP and IHD.
- Comparison Group (n=48): Patients diagnosed with HSP but without any underlying heart disease.
Diagnostic confirmation for HSP relied on a multi-modal approach: detailed allergic and occupational histories, respiratory symptom assessment, lung function tests (spirometry, body plethysmography, and DLCO), and high-resolution computed tomography (CT) scans. In some instances, diagnoses were further verified through bronchoalveolar lavage (BAL) or lung biopsy. Heart disease was classified according to the European Society of Cardiology (ESC) 2020 guidelines.
Results
The analysis demonstrated a clear disparity in diagnostic accuracy between the two groups.
Diagnostic Error Rates
The primary diagnostic error rate was significantly higher in the comorbid group, reaching 60.49%, compared to 44.88% in the group with isolated HSP. These errors often led to patients being misdiagnosed with pneumonia, chronic bronchitis, or asthma, resulting in prolonged courses of unnecessary antibiotics or ineffective bronchodilator therapy.
Functional and Imaging Discrepancies
Patients with both HSP and IHD showed significantly greater functional impairment. In the 6-minute walk test (6MWT), the comorbid group averaged only 298.3 meters, whereas the comparison group averaged 398.5 meters. This suggests that the combined burden of lung inflammation and cardiac insufficiency creates a synergistic decline in physical capacity.
Imaging misinterpretation was the most frequent source of error, occurring in 28.21% of the IHD group. The "ground-glass opacity" seen on CT scans—a hallmark of HSP—is often indistinguishable from pulmonary congestion or edema caused by heart failure without the use of high-resolution techniques and contrast.
Treatment Delays
Due to these diagnostic hurdles, the average time from symptom onset to a correct HSP diagnosis was delayed by 1.5 to 2 years in the comorbid group. This delay is critical, as chronic HSP can lead to irreversible lung fibrosis if not treated early with antigen avoidance or corticosteroids.
Discussion: The Mechanics of Misdiagnosis
Several factors contribute to the increased error rate in patients with IHD:
- Primary Condition Bias: Clinicians often fall victim to a "diagnostic stereotype." When a patient has a known, "heavier" diagnosis like IHD, doctors tend to attribute all new respiratory symptoms to cardiac failure, neglecting to investigate potential primary lung pathologies.
- Temporal Masking: In isolated HSP, symptoms often fluctuate based on environmental exposure (e.g., worsening during the workweek). However, the chronic, persistent fatigue associated with IHD masks these fluctuations, making it difficult for both the patient and the physician to identify an environmental trigger.
- Underutilization of DLCO: The Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) is one of the most sensitive early markers for HSP, often showing decline before X-ray changes appear. However, the study found it was only utilized in approximately 54-59% of cases, representing a missed opportunity for early detection.
Conclusion
The presence of Ischemic Heart Disease significantly complicates the diagnosis of Hypersensitivity Pneumonitis, leading to higher error rates and substantial delays in appropriate treatment. To improve outcomes, a multidisciplinary approach involving both cardiologists and pulmonologists is essential. Furthermore, general practitioners should be trained to look beyond "cardiac" dyspnea, utilizing early functional tests like DLCO and detailed occupational histories to uncover underlying interstitial lung diseases.
Summary updated